SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-024626
Filing Date
2023-07-14
Accepted
2023-07-14 17:26:05
Documents
15
Period of Report
2023-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47263
2 ex1-1.htm EX-1.1 305403
3 ex5-1.htm EX-5.1 22588
4 ex5-1_001.jpg GRAPHIC 7509
  Complete submission text file 0001493152-23-024626.txt   636188

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT immx-20230714.xsd EX-101.SCH 3015
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT immx-20230714_lab.xml EX-101.LAB 34916
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT immx-20230714_pre.xml EX-101.PRE 22789
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3565
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

IRS No.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41159 | Film No.: 231089884
SIC: 2834 Pharmaceutical Preparations